GORE® TAG® Thoracic Branch Endoprosthesis (TBE) Now Indicated for Zone 0 and Zone 1 Aortic Arch Repairs

The first off-the-shelf, on-label branched endovascular device for Zones 0, 1 and 2

FLAGSTAFF, Ariz. (June 23, 2025) — W. L. Gore & Associates Medical Products (Gore) today announced that the GORE® TAG® Thoracic Branch Endoprosthesis (TBE) is now FDA approved for use in Zones 0 and 1, expanding its indication for the endovascular repair of lesions in the aortic arch and descending thoracic aorta while preserving flow to a single aortic arch branch vessel.

The device — a proven solution for Zone 2 repair — becomes the first off-the-shelf, single-branch thoracic endoprosthesis indicated across Zones 0, 1 and 2, enabling or expanding minimally invasive aortic repair of all lesions involving the arch.

“With broader indications, we can confidently address a wider range of complex arch pathologies using a trusted solution that streamlines procedure planning and — critically — helps improve patient outcomes,” said Michael Dake, M.D., National Co-Principal Investigator of the GORE TAG Thoracic Branch Endoprosthesis Clinical Trial. “Of the 77 patients enrolled in the Zone 0/1 pivotal trial, more than 90 percent were treated in Zone 0 with no instances of device migration or wire fracture through 12 months, as well as low rates of Type I and III endoleaks.”

For Zone 0 and 1 procedures, TBE provides an on-label alternative to open surgical repair and reduces the overall impact of procedures like sternotomy, cardiopulmonary bypass and circulatory arrest.

“We’ve seen firsthand how this technology can transform patient care,” said Himanshu Patel, M.D., National Co-Principal Investigator. “With a less invasive approach, we can reduce a significant procedural burden on patients.”

For Gore’s Jason Belzer, Americas Business Leader, Medical Products Division, “The expanded indication equips physicians with a versatile solution for the challenges of treating aortic arch pathologies — with the backing of rigorous data and a track record of procedural success. We are excited that more patients will have access to this technology.”

First approved in the U.S. in May 2022, this new indication for the use of TBE in Zones 0/1 further demonstrates how Gore is advancing the care of complex aortic disease with minimally invasive approaches for patients

Medical Products

Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 55 million medical devices implanted over the course of more than 45 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. For more information, visit goremedical.com

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With approximately 13,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $5 billion. gore.com